<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536248</url>
  </required_header>
  <id_info>
    <org_study_id>JANU-INF</org_study_id>
    <nct_id>NCT02536248</nct_id>
  </id_info>
  <brief_title>Sitagliptin Therapy and Kinetics of Inflammatory Markers</brief_title>
  <official_title>EFFECTS OF SITAGLIPTIN THERAPY ON THE KINETICS OF MARKERS OF LOW-GRADE INFLAMMATION AND CELL ADHESION MOLECULES IN PATIENTS WITH TYPE 2 DIABETES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory processes are increasingly being recognized as a critical step in the
      pathogenesis of both diabetes and heart disease and may constitute a biological link between
      the two diseases. Inflammatory cytokines increase vascular permeability, change
      vasoregulatory responses, increase leukocyte adhesion to endothelium, and facilitate thrombus
      formation by inducing procoagulant activity, inhibiting anticoagulant pathways, and impairing
      fibrinolysis. Leukocyte adhesion to arterial endothelial cells is thought to be an important
      step in the development of atherosclerosis, and adhesion molecules, such as intercellular
      adhesion molecule-1 (ICAM-1) and L-selectin, play key roles in this process. Therefore,
      identifying novel therapeutic approaches that would favorably affect inflammation,
      endothelial function, and glucose is of significant interest. Investigators have recently
      demonstrated that, relative to placebo, sitagliptin treatment resulted in a significant
      reduction in plasma levels of various inflammatory markers and cell adhesion molecules. The
      results also suggest that the beneficial effects of sitagliptin on both inflammation and
      endothelial function are most likely mediated by an elevation in plasma GLP-1 levels and
      global improvement of the glucose-insulin homeostasis. However, the mechanisms underlying the
      beneficial effects of sitagliptin on these markers remain to be fully elucidated. The
      proposed study will address this key issue.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Serum Amyloid A Production Rate With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of L-selectin Production Rate With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg/d for 6 weeks
Wash-out 14 days
Placebo for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Sitagliptin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 6 weeks
Wash-out 14 days
Sitagliptin 100 mg/d for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg/d for 6 weeks</description>
    <arm_group_label>Placebo first, then Sitagliptin</arm_group_label>
    <arm_group_label>Sitagliptin first, then Placebo</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 6 weeks</description>
    <arm_group_label>Placebo first, then Sitagliptin</arm_group_label>
    <arm_group_label>Sitagliptin first, then Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 18 to 65 years of age.

          -  Post-menopausal women under age 65 on stable medical therapy for 6 months before the
             study (the patient should have demonstrated stable lipid panels)

          -  Women should not be on hormone replacement therapy (no recent starting or stopping)

          -  Type 2 diabetes as defined by the American Diabetes Association.

          -  Non-smoker.

          -  Body mass index between 25.0 and 40.0 kg/m2.

          -  Baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%.

          -  Baseline fasting plasma glucose &lt; 15.0 mmol/L.

          -  Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at screening
             and week -4.

          -  Patients having received stable doses of metformin for at least 3 months before
             randomization.

          -  Subjects must be willing to give written informed consent and able to adhere to dosing
             schedule, visit schedule and phone follow-up assessment.

          -  Patients should be otherwise generally healthy, without elevations in hepatic
             transaminases or abnormal renal function or coagulation.

          -  Patients having normal thyroid stimulating hormone at screening

        Exclusion Criteria:

          -  Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be
             excluded.

          -  Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic
             complications will be excluded.

          -  Patients having received or being treated with insulin or a thiazolidinedione within
             the past 6 months will be excluded.

          -  Patients taking any other hypoglycemic agent, other than metformin.

          -  Subjects will be excluded if they have cardiovascular disease (coronary heart disease,
             cerebrovascular disease or peripheral arterial disease) or if they are taking other
             medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers,
             thiazide diuretics, lipid lowering agents, significant alcohol intake etc.).

          -  Subjects who are in a situation or have any condition that, in the opinion of the
             investigator, may interfere with optimal participation in the study.

          -  Individuals with a history of mental instability, drug or alcohol abuse or individuals
             who have been treated or are being treated for severe psychiatric illness that, in the
             opinion of the investigator, may interfere with optimal participation in the study.

          -  History of alcohol or drug abuse within the past 2 years. Patients must not take
             alcohol during the study.

          -  Disorders of the hematologic, digestive, or central nervous systems, including
             cerebrovascular disease and degenerative disease, that would limit study evaluation or
             participation.

          -  Known impairment of renal function (serum creatinine levels &gt; 1.7 mg/dL for men),
             dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3
             ± 1 g).

          -  Active or chronic hepatobiliary or hepatic disease. In addition, patients with
             aspartate aminotransferase or alanine aminotransferase &gt;2 x upper limit of the
             laboratory reference range will be excluded.

          -  Subjects with coagulopathy (prothrombin time or partial thromboplastin time at Visit 1
             &gt;1.5 times control).

          -  Subjects with hemoglobin &gt;2 x the lower limit of the laboratory reference range will
             be excluded.

          -  Patients who are known to have tested positive for human immunodeficiency virus (HIV).

          -  Patients who are currently enrolled in another clinical study.

          -  Patients who have used any investigational drug within 30 days of the first clinic
             visit.

          -  Congestive heart failure New York Heart Association (NYHA) Class III or IV.
             Uncontrolled cardiac arrhythmias within 3 months of study entry.

          -  Uncontrolled diabetes mellitus (HbA1c&gt;8.5%) or other endocrine or metabolic disease
             known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on
             replacement doses of thyroid hormone are eligible for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Couture, MD, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Patrick Couture</investigator_full_name>
    <investigator_title>MD, PhD, FRCP</investigator_title>
  </responsible_party>
  <keyword>sitagliptin</keyword>
  <keyword>diabetes</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02536248/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02536248/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin First Then Placebo</title>
          <description>Sitagliptin 100 mg/d for 6 weeks
Wash-out 14 days
Placebo for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Sitagliptin</title>
          <description>Placebo for 6 weeks
Wash-out 14 days
Sitagliptin 100 mg/d for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin First Then Placebo</title>
          <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo First Then Sitagliptin</title>
          <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="4.6"/>
                    <measurement group_id="B2" value="58.5" spread="3.2"/>
                    <measurement group_id="B3" value="58.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <population>Results for this outcome are not available since we had issues with the measurement of deuterated leucine in the current protein (C-reactive protein).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period</title>
          <population>Results for this outcome are not available since we had issues with the measurement of deuterated leucine in the current protein (C-reactive protein).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Serum Amyloid A Production Rate With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Serum Amyloid A Production Rate With Stable Isotope During Postprandial Period</title>
          <units>mg/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.030"/>
                    <measurement group_id="O2" value="0.049" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of L-selectin Production Rate With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <population>Results for this outcome are not available since we had issues with the measurement of deuterated leucine in the current protein (L-selectin).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of L-selectin Production Rate With Stable Isotope During Postprandial Period</title>
          <population>Results for this outcome are not available since we had issues with the measurement of deuterated leucine in the current protein (L-selectin).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <population>Results for this outcome are not available since we had issues with the measurement of deuterated leucine in the current protein (I-CAM-1).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period</title>
          <population>Results for this outcome are not available since we had issues with the measurement of deuterated leucine in the current protein (I-CAM-1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Couture MD, PhD, FRCP</name_or_title>
      <organization>Laval university</organization>
      <phone>418-654-2106</phone>
      <email>patrick.couture@crchul.ulaval.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

